Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) ROCE % : 82.05% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Macro Group Pharmaceuticals (Macro Capital) Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROCE % for the quarter that ended in Sep. 2023 was 82.05%.

Macro Group Pharmaceuticals (Macro Capital) Co ROCE % Historical Data

The historical data trend for Macro Group Pharmaceuticals (Macro Capital) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macro Group Pharmaceuticals (Macro Capital) Co ROCE % Chart

Macro Group Pharmaceuticals (Macro Capital) Co Annual Data

Trend

Dec20

Dec21

Dec22

ROCE %

55.14

56.36

Macro Group Pharmaceuticals (Macro Capital) Co Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Sep23
ROCE %	Get a 7-Day Free Trial						46.89	62.93	78.58	54.21	82.05

Macro Group Pharmaceuticals (Macro Capital) Co ROCE % Calculation

Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	240.829	/	( ( (577.096 - 206.027)	+	(849.635 - 366.064) )	/ 2 )
	=	240.829	/	( (371.069	+	483.571)	/ 2 )
	=	240.829	/	427.32
	=	56.36 %

Macro Group Pharmaceuticals (Macro Capital) Co's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Dec. 2022 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Dec. 2022 )		(Q: Sep. 2023 )
	=	399.064	/	( ( (849.635 - 366.064)	+	(913.227 - 424.061) )	/ 2 )
	=	399.064	/	( ( 483.571	+	489.166 )	/ 2 )
	=	399.064	/	486.3685
	=	82.05 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Macro Group Pharmaceuticals (Macro Capital) Co ROCE % Related Terms

Thank you for viewing the detailed overview of Macro Group Pharmaceuticals (Macro Capital) Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Macro Group Pharmaceuticals (Macro Capital) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

83, Al Moltaka Al Arabi, Sheraton, Cairo, EGY

Website

https://www.macro-egy.com

Macro Group Pharmaceuticals (Macro Capital) Co is principally engaged in the manufacture and sale of cosmeceutical and ventured into nutraceutical products.